Fluphenazine (oral) versus atypical antipsychotics for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 11, 2013, Pages

  Sampford, James ^a   Sampson, Stephanie ^b  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; FLUPHENAZINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG EFFICACY; DRUG SAFETY; FUNCTIONAL STATUS; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MENTAL HEALTH; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84907277708     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010832     Document Type: Article

References (40)

1. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
2. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry 2004;161(Suppl 2):1-56.
3. Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
4. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: Comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
5. Darling HF. Fluphenazine: a preliminary study. Disease of the Nervous System 1959;20(4):167-70.
6. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
7. Dencker SJ, Johansson R, Malm U. Pharmacokinetic and pharmacodynamic studies on high doses of fluphenazine. Psychopharmacology (Berl) 1988;94(2):237-41.
8. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
9. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
10. Dysken MW, Javaid JI, Chang SS, Schaffer C, Shahid A, Davis JM. Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology (Berl) 1981;73(3):205-10.
11. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
12. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
13. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
14. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991;41(1):1-24.
15. Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
16. Healy D, Le Noury J, Harris M, Butt M, Linden S, Whitaker C, et al. Mortality in schizophrenia and related psychoses: data from two cohorts, 1875-1924 and 1994-2010. BMJ Open 2012;2(5):e001810. [DOI: 10.1136/bmjopen-2012-001810]
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
18. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
19. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
20. Jones PB, Barnes TRE, Davies L. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia - cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Archives of General Psychiatry 2006;63:1079-86.
21. Kane JM, Woerner M, Sarantakos S. Depot neuroleptics: A comparison review of standard, intermediate and low-dose regimens. Journal of Clinical Psychiatry 1986;47(Suppl 5):30-3.
22. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
23. Kendall T. The rise and fall of the atypical antipsychotics. British Journal of Psychiatry 2011;199:266-8.
24. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
25. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
26. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
27. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373(9657):31-41.
28. Lieberman JA, Stroup TS, McEvoy JP. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209-23.
29. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
30. Marvaha S, Johnson S. Schizophrenia and employment - a review. Social Psychiatry and Psychiatric Epidemiology 2004;39:337-49.
31. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiological Review 2008;30:67-76.
32. Millar J. A trial of fluphenazine in schizophrenia. British Journal of Psychiatry 1963;109:428-32.
33. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799-812.
34. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Medicine 2005;2(5):e141. [DOI: 10.1371/journal.pmed.0020141]
35. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
36. Seeman P. Atypical antipsychotics: mechanism of action. Canadian Journal of Psychiatry 2002;47(1):27-38.
37. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
38. van Os J, Rutten BPF, Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophrenia Bulletin 2008;34(6):1066-82.
39. Essential Medicines: WHO model list. http://whqlibdoc.who.int/hq/2005/a87017_eng.pdf March 2005; Vol. 14th edition.
40. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.